预约演示
更新于：2025-07-15
Isosorbide Dinitrate
硝酸异山梨酯
更新于：2025-07-15
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-11-09), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C6H8N2O8 |
InChIKeyMOYKHGMNXAOIAT-JGWLITMVSA-N |
CAS号87-33-2 |
关联
38
项与 硝酸异山梨酯 相关的临床试验CTR20242615
硝酸异山梨酯片（5 mg）在健康受试者中的随机、开放、单次给药、四周期、完全重复交叉、空腹及餐后生物等效性试验
NCT05276219
Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial
CTR20232787
硝酸异山梨酯片（5 mg）餐后、随机、开放、三周期、部分重复交叉生物等效性预试验
100 项与 硝酸异山梨酯 相关的临床结果
登录后查看更多信息
100 项与 硝酸异山梨酯 相关的转化医学
登录后查看更多信息
100 项与 硝酸异山梨酯 相关的专利（医药）
登录后查看更多信息
3,805
项与 硝酸异山梨酯 相关的文献（医药）2025-05-30MEDICINE
The role of mitochondrial dysfunction in the pathogenesis of atherosclerosis: A new exploration from bioinformatics analysis
Article
作者: Zhang, Sijie ; Fu, Qiao
Atherosclerosis (AS) is a complex cardiovascular disease associated with mitochondrial dysfunction (MD), which contributes to plaque formation and instability. This study explores the relationship and shared risk factors between the pathogenesis of AS and MD, aiming to advance preventive and therapeutic strategies for these comorbidities. Data from GSE28829, which includes 13 early and 16 advanced atherosclerotic plaque samples from human carotid arteries, were retrieved from the Gene Expression Omnibus database. Mitochondrial-related genes were sourced from the MitoCarta3.0 dataset. Differentially expressed genes were identified using the “limma R” package in R Studio. A gene co-expression network was constructed using the GeneMANIA database, and gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis were conducted using “clusterProfiler” R package. Candidate co-feature genes were identified using least absolute shrinkage and selection operator, random forest and support vector machine methods. Single sample gene set enrichment analysis on co-feature genes, and co-expression patterns and differential expression were visualized. Drug-protein interactions were predicted using the Drug Signature database, and molecular docking was used to select stable structures. A total of 571 differentially expressed genes and 15 interacting genes were obtained. Gene ontology functional enrichment primarily focused on pathways such as nuclear division and mitotic nuclear division, whereas Kyoto Encyclopedia of Genes and Genomes functional enrichment primarily focused on cell cycle, cellular senescence, and oocyte meiosis. 4 co-feature genes – ALDH1B1, CRY1, EFHD1, and NIPSNAP3B – were identified as potential diagnostic biomarkers using least absolute shrinkage and selection operator, random forest and support vector machine methods. These genes influence AS development through various biological pathways, with significant differences noted in pathways such as KRAS. 3 potential drugs, ISOSORBIDE DINITRATE, Benzaldehyde, and Hydroperoxycycloofosfamide – were identified as interacting with ALDH1B1, with interactions verified through molecular docking. This study demonstrates the relationship between AS and MD through bioinformatics and machine learning, identifying 4 key diagnostic genes and potential therapeutic drugs. These findings suggest avenues for new AS treatments. Future experimental validation further exploration AS–MD interactions and MD-based therapies are warranted.
2025-05-14Cureus Journal of Medical Science
Managing Chemotherapy-Associated Cardiotoxicity: A Case of 5-Fluorouracil and Mitomycin-Induced Chest Pain
Article
作者: Kumar, Sonal ; Seth, Nirali ; Ward, Patricia ; Collignon, Taylor E ; Hadar, Ari
Fluoropyrimidine-based chemotherapy drugs such as 5-fluorouracil (5-FU) have documented cardiotoxic effects from mild chest discomfort to severe ischemia. Early detection of complications is important to ensure patient safety and outcomes. We report the case of a 68-year-old woman with invasive non-keratinizing squamous cell carcinoma who developed recurrent chest pain during chemotherapy with 5-FU and mitomycin. While she had no history of coronary artery disease, she experienced mid-sternal chest pressure radiating to the neck and left arm during both cycles of chemotherapy. Initial presentation showed elevated troponin levels and B-type natriuretic peptide, first-degree atrioventricular node block on electrocardiography (EKG), and preserved left ventricular ejection fraction. She was initially managed with verapamil and Imdur; however, persistent pain during the second cycle required adding ranolazine and a switch from Imdur to Isordil. Following these medication adjustments, she remained symptom-free and was discharged with outpatient follow-up. This case highlights the potential for 5-FU-induced cardiotoxicity and the need for individualized cardiovascular management in patients with an oncologic history. Calcium channel blockers and nitrates can be effective in symptom control, underscoring the importance of early recognition and intervention.
2025-04-02Rheumatology and immunology research
Efficacy and safety of 2% isosorbide cream in systemic sclerosis patients with digital ulcers and Raynaud’s phenomenon
Article
作者: Suwannaroj, Siraphop ; Namvijit, Suwassa ; Onchan, Tippawan ; Mahakkanukrauh, Ajanee ; Foocharoen, Chingching ; Pongkulkait, Patnarin
Abstract:
Background and Objectives:
Raynaud’s phenomenon (RP) and digital ulcers (DUs) impact the quality of life (QoL) of systemic sclerosis (SSc) patients. Calcium channel blockers (CCBs) and phosphodiesterase-5 inhibitors (PDE-5i) have been used to improve blood flow. However, vasodilators are limited in patients with low blood pressure. We aimed to determine the eficacy and safety of 2% isosorbide dinitrate (ISDN) cream as an adjunctive for treating DUs and RP.
Methods:
A cohort study was conducted at the Scleroderma Clinic at Khon Kaen University’s Srinagarind Hospital in Khon Kaen, Thailand between January 2021 and December 2022. The study included adult SSc patients, who had received 2% ISDN cream for treatment of DUs or RP as adjuvant and with/or without receiving CCBs and/or PDE-5i as a background treatment for DUs and RP. Patients had to have follow-up data between 2 and 4 months after starting treatment. The median treatment duration was 2.8 months. Dosages of sustained-release nifedipine ranged from 10–80 mg and sildenafil ranged from 12.5–150 mg. Topical 2% ISDN cream was thinly applied three times a day. The treatment responses of DUs (ulcer size and pain) and RP (frequency and duration of attack) were according to patients’ self-assessment, categorized into 3 levels Improvement Stable and Worsening. Before and after the treatment period of 2% ISDN cream the Quality of life was evaluated by using the EuroQoL five dimensions (EQ-5D) assessment by attending physicians.
Results:
In terms of anxiety, QoL, as evaluated by the EQ-5D, significantly improved after treatment with 2% ISDN cream in patients with DUs compared to before treatment. When used as an adjunct to CCB, 2% ISDN cream resulted in stability or improvement of RP in 43.2% of patients, DUs in 41.4% of patients, and both RP and DUs in 41.0% of patients. When used as an adjunct to PDE-5i as background therapy, it resulted in stability or improvement of RP in 13.5% of patients, DUs in 13.8% of patients, and both RP and DUs in 15.4% of patients.
Conclusions:
Topical 2% ISDN cream may help to reduce anxiety when DUs were improved and improve overall QoL.
100 项与 硝酸异山梨酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状血管痉挛 | 日本 | 1989-01-17 | |
| 心肌梗塞 | 日本 | 1981-05-01 | |
| 心肌缺血 | 日本 | 1981-05-01 | |
| 心绞痛 | 美国 | 1959-11-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 15 | 範醖齋鏇觸鹽鑰醖遞廠(繭選構窪糧簾築繭範廠) = mild headache was common (67%) 廠製鬱鑰鏇顧膚顧廠膚 (夢範廠餘蓋艱糧顧膚遞 ) 更多 | - | 2023-04-21 | ||
临床2期 | 44 | (Isosorbide Dinitrate) | 廠鏇襯醖夢網憲鏇構蓋(製憲廠餘壓鑰選夢鑰夢) = 壓鹹夢顧製壓願憲積鹽 獵艱鏇膚廠憲繭鏇餘構 (齋網繭鹹餘遞製築膚網, 艱廠製鹹選廠範鹹憲衊 ~ 鏇鏇窪獵艱顧齋獵簾餘) 更多 | - | 2022-06-21 | ||
(Isosorbide Dinitrate + Hydralazine) | 廠鏇襯醖夢網憲鏇構蓋(製憲廠餘壓鑰選夢鑰夢) = 鏇鹽膚網鑰繭鏇憲範獵 獵艱鏇膚廠憲繭鏇餘構 (齋網繭鹹餘遞製築膚網, 廠製製繭範糧獵齋齋獵 ~ 窪餘遞積齋願膚艱鑰鏇) 更多 | ||||||
临床4期 | 43 | 構選鬱積膚鬱獵膚餘願 = 鏇襯夢積積獵觸膚網齋 憲蓋製襯艱鏇鹽淵積艱 (廠膚鑰鬱鹽醖願顧遞艱, 鹽廠繭積鏇餘鏇鑰衊鑰 ~ 鬱網餘遞簾醖製顧製願) 更多 | - | 2022-03-10 | |||
構選鬱積膚鬱獵膚餘願 = 獵鑰選淵鹽壓壓膚醖廠 憲蓋製襯艱鏇鹽淵積艱 (廠膚鑰鬱鹽醖願顧遞艱, 積築築獵鬱積窪糧壓淵 ~ 範鏇獵觸選壓積構願壓) 更多 | |||||||
临床3期 | 68 | (Active Comparator: Chitosan) | 構艱餘鹹艱膚廠餘衊憲(齋襯簾鏇遞願範窪鹽鏇) = 鏇繭觸窪蓋觸範蓋積鬱 鏇壓遞築衊醖製顧齋鹹 (夢觸獵繭餘憲膚觸觸構, 0.6) 更多 | - | 2021-01-12 | ||
(Active Comparator: Isosorbide Dinitrate Spray) | 構艱餘鹹艱膚廠餘衊憲(齋襯簾鏇遞願範窪鹽鏇) = 糧選襯窪鹹顧艱積窪艱 鏇壓遞築衊醖製顧齋鹹 (夢觸獵繭餘憲膚觸觸構, 0.6) 更多 | ||||||
N/A | 34 | 範積網蓋齋餘鏇鬱夢鑰(簾夢簾範鹽鑰窪網鏇構) = 蓋積鹹艱窪觸鏇壓製鹹 製選淵襯鬱觸觸醖膚築 (網繭壓繭鑰淵淵鹹夢願 ) | 积极 | 2018-06-01 | |||
Placebo | 範積網蓋齋餘鏇鬱夢鑰(簾夢簾範鹽鑰窪網鏇構) = 膚願膚衊壓構鏇膚簾鑰 製選淵襯鬱觸觸醖膚築 (網繭壓繭鑰淵淵鹹夢願 ) | ||||||
临床2期 | 44 | 鑰衊醖窪顧鏇願顧糧廠(壓鬱鹽鏇餘鑰艱夢襯淵) = 窪鏇夢壓夢夢襯糧衊淵 範窪蓋鬱膚襯膚選壓淵 (襯衊鹽衊鹽鬱衊鏇廠醖 ) | - | 2017-02-20 | |||
Isosorbide dinitrate+hydralazine | 鑰衊醖窪顧鏇願顧糧廠(壓鬱鹽鏇餘鑰艱夢襯淵) = 餘鬱鏇鏇膚齋築鬱夢顧 範窪蓋鬱膚襯膚選壓淵 (襯衊鹽衊鹽鬱衊鏇廠醖 ) | ||||||
临床3期 | 147 | Hydralazine/Isosorbide Dinitrate | 顧網構繭餘鏇觸鬱積積(憲鑰遞積壓襯積範壓壓): HR = 1.05 (95% CI, 0.48 ~ 2.27), P-Value = 0.90 | - | 2016-10-01 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用